BioSenic S.A. (EBR:BIOS)

Belgium flag Belgium · Delayed Price · Currency is EUR
0.0026
+0.0001 (4.00%)
Mar 2, 2026, 9:41 AM CET
Market Cap1.63M -17.3%
Revenue (ttm)-2.39M -69.6%
Net Income-4.00M
EPS-0.01
Shares Out652.86M
PE Ration/a
Forward PEn/a
Dividendn/a
Ex-Dividend Daten/a
Volume168,162
Average Volume1,427,219
Open0.0023
Previous Close0.0025
Day's Range0.0023 - 0.0026
52-Week Range0.0012 - 0.0035
Beta-2.29
RSI55.72
Earnings DateApr 24, 2026

About BioSenic

BioSenic S.A., a biotechnology company, develops cell therapy products and treatments for autoimmune and inflammatory diseases in Belgium and France. The company offers arsenic trioxide (ATO) and oral arsenic trioxide (OATO) platforms. It also provides medicinal products, including ArsciMed, an intravenous drug to treat autoimmune diseases. In addition, the company develops 4P004v which is in Phase I clinical trial for veterinary use. BioSenic S.A. is headquartered in Saintes, Belgium. [Read more]

Industry Biotechnology
Sector Healthcare
CEO Jean-Luc Vandebroek
Employees 7
Stock Exchange Euronext Brussels
Ticker Symbol BIOS
Full Company Profile

Financial Performance

In 2024, BioSenic's revenue was 102,000, a decrease of -69.64% compared to the previous year's 336,000. Losses were -4.77 million, -83.43% less than in 2023.

Financial Statements